SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ZLDPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 78.53M
March 31, 2026 77.27M
December 31, 2025 75.49M
September 30, 2025 83.21M
June 30, 2025 67.14M
March 31, 2025 62.01M
December 31, 2024 58.48M
September 30, 2024 45.64M
June 30, 2024 39.08M
March 31, 2024 35.51M
December 31, 2023 31.33M
September 30, 2023 30.89M
June 30, 2023 31.78M
March 31, 2023 35.24M
December 31, 2022 38.21M
September 30, 2022 39.79M
June 30, 2022 43.27M
March 31, 2022 58.69M
December 31, 2021 70.25M
September 30, 2021 92.68M
June 30, 2021 102.72M
March 31, 2021 93.52M
December 31, 2020 75.90M
September 30, 2020 45.62M
June 30, 2020 26.34M
Date Value
March 31, 2020 11.67M
December 31, 2019 10.18M
September 30, 2019 9.754M
June 30, 2019 8.972M
March 31, 2019 7.183M
December 31, 2018 6.305M
September 30, 2018 6.865M
June 30, 2018 6.513M
March 31, 2018 7.131M
December 31, 2017 7.227M
September 30, 2017 7.755M
June 30, 2017 7.283M
March 31, 2017 8.218M
December 31, 2016 7.912M
September 30, 2016 7.214M
June 30, 2016 7.761M
March 31, 2016 6.595M
December 31, 2015 6.613M
September 30, 2015 7.407M
June 30, 2015 7.102M
March 31, 2015 6.64M
December 31, 2014 6.977M
September 30, 2014 5.692M
June 30, 2014 5.997M
March 31, 2014 6.310M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Genmab A/S 726.50M
Ascendis Pharma A/S 662.10M
Bavarian Nordic A/S 218.74M
Evaxion AS 4.527M
Novo Nordisk A/S 10.12B